Fig. 3From: Overexpression of G6PD is associated with high risks of recurrent metastasis and poor progression-free survival in primary breast carcinomaKaplan-Meier survival curves of the patients with breast carcinoma according to the G6PD immunostaining results. Patients with G6PD-positive expression had shorter progression-free survival (PFS) time than those with G6PD-negative expression (log-rank test, P = 0.002)Back to article page